6th Multi-Channel Sampling Strategies Conference

NEW LEGISLATIVE REQUIREMENTS - Featured Regulatory Perspective

1:20
Navigating Vermont's Recently Passed S.88 Bill: The Disclosure and Reporting Process for All Samples Disseminated in Vermont

• Why you should have already begun tracking your distributed samples
• How the sample reporting system was deisgned and how it will work
• Differences between the Vermont law and the Patient Protection & Affordable Care Act of 2010

Presenter
Wendy Morgan
Assistant Attorney General
VERMONT ATTORNEY GENERAL'S OFFICE

In response to the Medicare Payment Advisory Commission recommendations made in a March 2009 report, The Physician Payments Sunshine Act was passed March 21st, 2010 and it requires manufacturers of drugs and medical devices, starting March 31, 2011 to report to HHS payments and transfers of value made to physicians and other health care providers.

For drug samples, the bill requires reporting of recipient information and the name, number, date, and dosage units of the sample.

On May 27th, 2010 Vermont passed S.88, which means beginning on or before April 1st, 2012, companies must disclose all samples that have been distributed in Vermont during the prior calendar year. Sentiment is that other states are to follow.

This increased transparency between the relationship of physician and pharmaceutical company means manufacturers not only have to meet the requirements, but also prepare their sales forces for decreased access to healthcare providers. New complementing multi-channel strategy must be developed to continue sample distribution as a critical component for overall success.